1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Greenyn Biotechnology Co., Ltd.

Greenyn Biotechnology Co., Ltd.

TTPEX:6846
57.90
TWD
-0.40
(-0.69%)
3.98EPS
14.17P/E
1.80BMarket Cap
Nov 12Next Earn
Greenyn Biotechnology Co., Ltd.
TPEX:6846
(Taipei Exchange)

Recent

price

57.90

P/E

ratio

14.17

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
25.4
28.68
28.54
28.89
30.89
32.49
33.9
32.04
Revenue per Share
4.12
5.35
5.46
6.01
5.04
5.43
5.39
4.7
Basic EPS, GAAP
4.86
10.81
2.63
8.71
1.46
7.81
-8.75
-12.32
Free Cash Flow per Basic Share
0.42
1.3
1.99
8.2
3.67
3.49
3.6
- -
Dividend per Share
15.91
21.23
25.14
23.02
29.7
31.55
36.21
33.92
Book Value per Share
15.88
21.2
25.09
22.96
29.63
31.43
36.1
33.81
Tangible Book Value per Share
23
23
24
24
26
27
27
27
Basic Weighted Avg Shares
584
663
694
705
801
873
915
868
Sales/Revenue/Turnover
22.2
24.1
24.38
23.63
20.09
19.22
20.63
18.18
Operating Margin (%)
30
29
23
25
25
31
35
41
Depreciation Expense
95
124
133
147
131
146
146
127
Net Income, GAAP
25.76
21.37
21.44
20.26
21.21
20.52
21.33
21.53
Effective Tax Rate (%)
16.2
18.65
19.14
20.8
16.32
16.72
15.9
14.67
Profit Margin (%)
234
397
494
440
535
638
1,268
1,210
Working Capital
61
50
43
46
56
52
901
1,210
LT Debt
388
518
614
562
797
851
979
918
Total Equity
- -
21.01
19.64
19.37
15.09
13.68
10.38
6.49
Return on Invested Capital (%)
- -
21.39
20.27
22.19
16.09
15.41
11.02
7.38
Return on Capital (%)
- -
27.25
23.46
24.96
19.23
17.72
15.9
14.03
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
15
9
7
LT Borrowings
862
973
1,201
LT Finance Leases
39
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
1,987
1,919
1,803

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,485
1,552
1,530
Cash, Cash Equivalents & STI
1,154
1,218
1,184
Accounts Receivable, Net
109
101
91
Inventories
178
194
205
Total Current Liabilities
217
403
320
Payables & Accruals
- -
- -
- -
ST Debt
15
9
7
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.71%
14.94%
Free Cash Flow
- -
63.8%
-212.53%
Net Income, GAAP
- -
3.69%
-0.33%
Sales/Revenue/Turnover
- -
6.76%
4.82%
Total Cash Common Dividend
- -
65.02%
3.44%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
226
191
210
246
873
2025
233
209
205
268
915
2026
198
196
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
0.93
1.08
1.86
5.43
2025
1.65
0.74
1.11
1.89
5.39
2026
1.15
0.55
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.49
2025
- -
- -
- -
- -
3.6
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Greenyn Biotechnology Co., Ltd (6846.TWO) develops and manufactures botanical extraction equipment and related solutions for the biotechnology and natural product industries. The company offers core products including supercritical CO2 extraction systems, ultrasonic extraction equipment, spray drying machines, and distillation units; services encompass customized system design, installation, maintenance, and technical consulting for herbal extraction processes. Headquartered in Taoyuan, Taiwan, Greenyn was founded in 2012 and primarily serves customers in the nutraceutical, cosmetics, food and beverage, and pharmaceutical sectors across Asia, with expanding operations in Europe and North America. Greenyn Biotechnology operates within the industrial machinery segment focused on green extraction technologies, targeting manufacturers seeking sustainable alternatives to chemical solvents for plant-based compounds. Its equipment supports production of high-purity extracts such as essential oils, cannabinoids, and polyphenols, emphasizing energy efficiency and compliance with international standards like GMP and FDA guidelines. The company maintains a network of subsidiaries and partnerships in key markets to facilitate global distribution and after-sales support. In recent developments, Greenyn Biotechnology announced a strategic partnership with a leading European nutraceutical firm in early 2025 to co-develop next-generation CO2 extraction systems optimized for hemp and medicinal plant processing, enhancing its presence in the burgeoning cannabis-derived product market. The company secured a NT$500 million funding round in late 2024 led by domestic venture capital, earmarked for R&D expansion and capacity upgrades at its Taoyuan facility. Additionally, Greenyn launched its GYN-SuperCritic 500L series in mid-2025, featuring AI-integrated controls for 20% higher yield efficiency, marking a shift toward smart manufacturing solutions.